- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03479554
China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Stroke is the leading cause of death in China and the second leading cause of death in the world. In addition, stroke is the leading cause of long-term disability worldwide and a major financial burden to society. It is estimated that there are probably more than 3 million new strokes every year in China. In 2013, more than 1.9 million Chinese adults died from stroke, which represented an increase of 47.7% from 1.3 million in 1990.
Elevated blood pressure (BP) is common in the acute phase of ischemic stroke, occurring in ≥75% of all patients. The early BP increase following ischemic stroke often reflects uncontrolled chronic hypertension. In addition, the potential causes of this transient rise include disturbed cerebral autoregulation, damage or compression of brain regions that regulate BP, neuroendocrine disturbance, and non-specific mechanisms such as headache, urine retention, and psychological stress. Several clinical trials have tested the effects of immediate BP lowering on adverse clinical outcomes in patients with acute ischemic stroke and showed a neutral effect on death or dependency. The China Antihypertensive Trial in Acute Ischemic Stroke (CATIS) suggested a beneficial effect of BP lowering on death or major disability (odds ratio [OR] 0.73, 95% confidence interval [CI] 0.55-0.96, p=0.03) and recurrent stroke (OR 0.25, 95% CI 0.08-0.74, p=0.01) among patients with acute ischemic stroke who received antihypertensive treatment between 24-48 hours in a subgroup analysis. There are important knowledge gaps in BP management in acute ischemic stroke, such as when is the optimal time for initiation of antihypertensive treatment.
The investigators propose to conduct a multicenter randomized controlled trial to test the primary hypothesis of whether early antihypertensive treatment starting between the first 24-48 hours after the onset of an acute ischemic stroke will reduce the risk of composite case-fatality and major disability (modified Rankin scale score ≥3) at three months compared to delayed antihypertensive treatment (starting on day 8 after stroke onset). Patients with acute ischemic stroke will be randomly assigned within the first 24-48 hours after stroke onset to the early and delayed treatment groups. Patients in the early treatment group will immediately receive antihypertensive treatment aimed at lowering average systolic BP by 10-20% (with a mean reduction of 15%) within the first 24 hours, achieving an average systolic/diastolic BP <140/90 mmHg within seven days, and maintaining this level afterward. Patients in the delayed treatment group will discontinue antihypertensive medications for the first seven days. After then, both groups will receive antihypertensive treatment with an average systolic/diastolic BP goal of <140/90 mmHg. The primary study endpoint will be a composite outcome of death and major disability (modified Rankin Scale score ≥3) at three months after randomization. The major secondary endpoint will be the first recurrent stroke (hemorrhagic or ischemic) within three months. Other secondary endpoints include ordered 7-level categorical score of the modified Rankin Scale, all-cause mortality, and major vascular events at three months.
In the proposed China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2), the investigators will recruit 4,776 patients (2,388 for each group) from 100 hospitals within the China Stroke Clinical Research Network. Eligibility criteria for the trial participants include age ≥40 years, acute ischemic stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI), symptom onset between 24-48 hours, and an average systolic BP between 140-200 mmHg. The proposed study provides 85% statistical power to detect a 15% reduction in the primary study endpoint at three months at a significance level of 0.05 for a two-sided test. Based on experience from our previous CATIS trial, we assumed an event rate of 25% for the primary study outcome and potential loss to follow-up of 5% over three months. To achieve the CATIS-2 study objectives, we plan to:
- Recruit and randomize 4,776 eligible patients (2,388 for each group) to the early antihypertensive treatment group or the delayed antihypertensive treatment group according to the study eligibility criteria;
- Achieve and maintain target treatment goals for BP in the randomization groups;
- Follow a study-wide strategy to encourage a standard of care based on clinical guidelines for the treatment of acute ischemic stroke other than BP for all participants;
- Obtain follow-up data on clinical endpoints, neurological and functional status for each participant according to the study protocol; and
- Estimate the effect of early antihypertensive treatment vs. delayed treatment on the primary and secondary endpoints according to intention-to-treat analysis and conduct predefined subgroup analyses.
The CATIS-2 study will provide important information for the development of clinical guidelines in the early management of BP among patients with acute ischemic stroke for reducing mortality and major disability.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Jiang He, MD, PhD
- Phone Number: 504-988-5165
- Email: jhe@tulane.edu
Study Contact Backup
- Name: Yilong Wang, MD, PhD
- Phone Number: 01186-13911666571
- Email: yilongwang528@aliyun.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Beijing Tiantan Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women aged ≥40 years
- Acute ischemic stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) of the head
- Stroke onset within 24-48 hours*
- Systolic blood pressure between 140-200 mmHg and diastolic blood pressure between 80-120 mmHg
Exclusion Criteria:
- Hemorrhagic stroke confirmed by CT or MRI of the head
- CT or MRI-diagnosed vascular malformation, tumor, abscess, or other major non-ischemic brain disease (e.g., multiple sclerosis)
- Extracranial or intracranial artery stenosis (≥70%) in both sides or the affected side based on imagine study
- Stroke caused by arteritis, migraine, vasospasm, or substance abuse
- Severe stroke (NIHSS score of ≥21)
- Coma (Glasgow Coma Scale [GCS] score <8)
- Preceding moderate or severe dependency (modified Rankin scale [mRS] score 3-5)
- Planned or probable revascularization (any angioplasty or vascular surgery) within 3 months after screening
- Intravenous thrombolytic therapy (such as intravenous rtPA) or mechanical thrombectomy
- Severe heart failure (NY Heart Association class III and IV) or left ventricular ejection fraction <35%
- Myocardial infarction or unstable angina within past 3 months
- History of atrial fibrillation.
- History of aortic dissection
- History of all-cause dementia
- Difficult-to-control hypertension (systolic blood pressure ≥170 mmHg despite use of ≥4 antihypertensive medications for ≥6 months)
- Acute renal failure or dialysis or estimated glomerular filtration rate (eGFR) <20 ml/min/1.73 m2
- Any clinical conditions judged by the clinic team to likely limit the adherence to study procedures
- Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders
- Unable to participate in the follow-up examination (e.g., cannot travel to the participating hospital)
- Participation in another clinical trial within 30 days
- Pregnant, currently trying to become pregnant, or of child-bearing potential and not using birth control
- Failure to obtain informed consent from a participant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Early antihypertensive treatment group
BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group.
|
The CATIS 2 trial is designed to test BP reduction strategies-early antihypertensive treatment vs. delayed antihypertensive treatment-rather than test the efficacy of individual antihypertensive drugs. Several antihypertensive agents, including angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics will be used in the trial. BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group. The target treatment goals are:
|
Active Comparator: Delayed antihypertensive treatment group
All home antihypertensive medications will be discontinued in the first seven days after randomization.
Study participants will receive antihypertensive treatment on day eight after randomization.
|
All home antihypertensive medications will be discontinued in the first seven days after randomization.
Study participants will receive antihypertensive treatment on day eight after randomization and will target systolic BP <140 mmHg (but not lower than 120 mmHg) and diastolic BP <90 mmHg (but not lower than 70 mmHg) in two weeks.
A BP check-up visit will be conducted in two weeks.
If BP treatment goal is not achieved, antihypertensive medication will be titrated or a new medication will be added.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite outcome of death and major disability
Time Frame: At 3 months
|
The primary endpoint for the CATIS-2 trial is a composite outcome of death and major disability (modified Rankin score ≥3) at 3 months.
|
At 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrent stroke
Time Frame: At 3 months
|
The first recurrent stroke event (hemorrhagic or ischemic) over three months of follow-up.
|
At 3 months
|
Modified Rankin Scale
Time Frame: At 3 months
|
Ordered 7-level categorical score of the modified Rankin Scale
|
At 3 months
|
All-cause mortality
Time Frame: At 3 months
|
Total mortality from all causes
|
At 3 months
|
Major vascular disease events
Time Frame: At 3 months
|
Vascular deaths, non-fatal stroke, non-fatal myocardial infarction, coronary revascularization, hospitalized or treated angina, and hospitalized or treated congestive heart failure
|
At 3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jiang He, MD, PhD, Tulane University
- Principal Investigator: Yilong Wang, MD, PhD, Beijing Tiantan Hospital
- Principal Investigator: Liping Liu, MD, PhD, Beijing Tiantan Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1109725
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Ischemic Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAcute Ischemic Stroke (AIS)United States
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalCompletedIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Anaconda Biomed S.L.Not yet recruitingAcute Ischemic Stroke From Large Vessel Occlusion
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
Clinical Trials on Delayed antihypertensive treatment
-
University of California, San DiegoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Merz North America, Inc.Ulthera, IncCompletedImprovement in Skin Laxity of the Lower Face and SubmentumChina
-
Baylor College of MedicineCompletedAttention Deficit and Disruptive Behavior Disorders | Attention Deficit Hyperactivity DisorderUnited States
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic Obstructive
-
Technische Universität DresdenFederal Ministry of HealthUnknownCannabis Use DisordersGermany
-
University of North Carolina, Chapel HillStanford University; Centers for Disease Control and PreventionCompleted
-
BlueWind MedicalRecruiting
-
New York UniversityPlanned Parenthood Federation of AmericaCompletedBehavior and Behavior MechanismsUnited States
-
University of BirminghamBUPA FoundationUnknown
-
Case Western Reserve UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMultiple SclerosisUnited States